At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 289 enrolled
Drug / intervention
CC-220 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
In Brief
A Phase 2 clinical trial evaluating CC-220 and Placebo for Lupus Erythematosus, Systemic. Completed, enrolled 289 participants across 184 sites in 15 countries.
Detailed Summary
The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus. Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus, Systemic
CountriesArgentina, Belgium, Brazil, Canada, Colombia, France, Germany, Hungary, Italy, Mexico, Poland, Russia, Serbia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartAug 2017
Primary CompletionAug 2021
TodayJul 2026
First PostedMay 19, 2017
Enrollment StartAug 31, 2017
Primary CompletionAug 3, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.1 years ago
Interventions
CC-220drug
CC-220
Placeboother
Placebo QD PO